Прямой ингибитор ренина алискирен –инновационная стратегия антигипертензивнойтерапии

1. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
2. ОССН ВНОК. Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (второй пересмотр). Сердеч. недостаточность. 2005; 2 (36): 2–21.
3. Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hyperten Rep 2008; 10 (6): 496–503.
4. Auchus RA. Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr Opin Nephrol Hypertens 2003; 12: 153–8.
5. Пальцев М.А., Серов В.В. Эндокринная система почек и нефрогенная гипертензия. Тер. арх. 1987; 8: 110–3.
6. Stella A, Zanchetti A. Control of renal renin release. Kidney Int 1987; 31 (Suppl. 20): 89–94.
7. Fisher NDL, Hollenberg NK. Renin inhibition: whar are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592–9.
8. Nguyen G, Delarue F, Burckl_ C et al. Pivotal role of the renin/pro-renin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417–27.
9. Danser AHJ, Deinum J. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005; 46: 1069–76.
10. Oliver JA. Receptor mediated actions of renin and pro-renin. Kidney Int 2006; 69: 13–5.
11. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105–13.
12. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15 (2): 276–82.
13. Stephan D, Grima M, Welsch M et al. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system. Fundam Clin Pharmacol 1996; 10 (5): 474–83.
14. Azizi M, Chatellier G, Guyene TT et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92 (4): 825–34.
15. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.
16. Bleich M, Greger R. Mechanism of action of diuretics. Kidney Int 1997; 51 (Suppl. 59): S11–S15.
17. Johnson CA, Wakerlin GE. Antiserum for renin. Proc Soc Exp Biol Med 1940; 44: 277–81.
18. Haber E, Burton J. Inhibitors of the renin and their utility in physiologic studies. Fed Proc 1979; 38: 2768–73.
19. Boger J, Lohr NS, Ulm EH et al. Novel renin inhibitors containing the amino acid statine. Nature 1983; 303 (5912): 81–4.
20. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449–56.
21. Kleinert HD, Martin D, Chekal MA et al. Effects of renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension 1988; 11: 613–9.
22. Himmelmann A, Bergbrant A, Svensson A et al. Remikiren (Ro 42-5892)-an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am J Hypertens 1996; 9: 517–22.
23. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002; 39: e1–e8.
24. Azizi M, Menard J, Bissery A et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II–renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126–33.
25. Fisher ND, Jan Danser AH, Nussberger J et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117 (25): 3199–205.
26. Oh B-H, Mitchell J, Herron JR et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157–63.
27. Dahlöf B, Anderson DR, Arora V et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension (abstr). J Clin Hypertens 2007; 9 (Suppl. A): A157.
28. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Сердце. 2005; 4 (3): 120–6.
29. Jordan J, Engeli S, Boye SW et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047–55.
30. Schmieder RE, Philipp T, Guerediaga J et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417–25.
31. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomiased. Double-blind trial. Lancet 2007; 370: 221–9.
32. Yarows SA, Oparil S, Patel S et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008; 25 (12): 1288–302.
33. Luetscher JA, Kraemer FB, Wilson DM et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular comlications. N Engl J Med 1985; 312: 1412–7.
34. Chiarelli F, Pomilio M, De Luca FA et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol 2001; 16: 116–20.
35. Kelly DJ, Zhang Y, Moe G et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50 (11): 2398–404.
36. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46 (3): 569–76.
37. Persson F, Rossing P, Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73 (12): 1419–25.
38. Parving HH, Persson F, Lewis JB et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358 (23): 2433–46.
39. Solomon SD, Appelbaum E, Manning WJ et al. Effect of the Direct Renin Inhibitor Aliskiren, Either Alone or in Combination With Losartan, Compared to Losartan, on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy: The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. Presented at the American College of Cardiology, 57th Annual Scientific Session, March 31st, 2008.
40. McMurray JJV, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation-Heart Failure 2008; 1: 17–24.
41. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009 Jan 14. [Epub ahead of print] 1 of 9.
42. Dieterle W, Corynen S, Mann J. Effect of the oral rennin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 58: 433–6.
43. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral rennin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43: 527–35.

И.Е.Чазова, В.В.Фомин, М.А.Разуваева